WO2013115741A1 - Compositions pharmaceutiques contenant un inhibiteur de l'alpha-glucosidase - Google Patents

Compositions pharmaceutiques contenant un inhibiteur de l'alpha-glucosidase Download PDF

Info

Publication number
WO2013115741A1
WO2013115741A1 PCT/TR2013/000050 TR2013000050W WO2013115741A1 WO 2013115741 A1 WO2013115741 A1 WO 2013115741A1 TR 2013000050 W TR2013000050 W TR 2013000050W WO 2013115741 A1 WO2013115741 A1 WO 2013115741A1
Authority
WO
WIPO (PCT)
Prior art keywords
voglibose
acarbose
miglitol
pharmaceutical composition
range
Prior art date
Application number
PCT/TR2013/000050
Other languages
English (en)
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2013115741A1 publication Critical patent/WO2013115741A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Definitions

  • the present invention relates to pharmaceutical compositions comprising alpha-glucosidase derivative active agents or pharmaceutically acceptable derivatives thereof or combinations of these active agents with different substances that shall be used in the treatment of non-insulin dependent type II diabetes.
  • Alpha-glucosidase inhibitors prevent the digestion of carbohydrates and therefore production of monosachharides that are absorbed through the intestine. By this way, they affect blood sugar level positively.
  • the active agents known as alpha-glucosidase inhibitors are principally voglibose, acarbose and miglitol. Bioavailability characteristics of the products taken by the oral route are closely related to their dissolutions. When the compositions having low dissolution are taken by the patients, the active agent cannot reach sufficient therapeutic amounts in body as a result of insufficient dissolution of the active agent taken in the body and this affects the treatment negatively.
  • compositions when the pharmaceutical compositions are formed into various dosage forms they should have content uniformity therefore comprise equal amounts of active agent in unit dosage form. This depends on flow characteristics of the formulations prepared. Each unit dose of the formulations having free flow property comprises equal amount of active agent. By this respect, content uniformity is provided and patients can take equal and precise amount of the drug per drug intake.
  • the inventors have surprisingly achieved to develop formulations comprising voglibose, acarbose or miglitol having both free flow and good dissolution properties.
  • the formulations comprising voglibose, acarbose or miglitol as the active agent wherein - the ratio of bulk density to compressed density is minimum 0.75, preferably in the range of 0.8 to 0.99 and more preferably in the range of 0.82 to 0.95 and
  • voglibose, acarbose or miglitol is in the range of 10 to 600 ⁇ have both free flow and good dissolution properties.
  • dgs signifies that 95% of the said substance by volume has a particle size below the value stated with and 5% of the said substance by volume has a particle size over the value stated with d95.
  • d 95 value of voglibose, acarbose or miglitol is preferably in the range of 15 to 550 ⁇ , more preferably in the range of 20 to 500 ⁇ , for instance in the range of 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105 to 120, 130, 140, 150, 160, 200, 250, 300, 350, 400, 450 ⁇ .
  • the present invention relates to formulations comprising voglibose, acarbose or miglitol as the active agent wherein the bulk density is in the range of 0.10 g/ml to 10 g/ml, preferably in the range of 0.15g/ml to 9 g/ml, more preferably in the range of 0.2 g/ml to 8.5 g/ml and the compressed density is in the range of 0.12 g/ml to 14 g/ml, preferably in the range of 0.15 g/ml to 13.5 g/ml, more preferably in the range of 0.2 g/ml to 13.0 g/ml.
  • Voglibose, acarbose or miglitol comprised in the pharmaceutical compositions of the present invention is in the form its pharmaceutically acceptable salts, hydrates, solvates, esters, enantiomers, diastereomers or combinations thereof in terms of chemical structure.
  • Voglibose, acarbose or miglitol comprised in the pharmaceutical compositions of the present invention is in amorphous or crystalline form or a combination thereof in terms of polymorphic structure.
  • the term d 95 can be measured with one of the known measuring devices, for instance with a device which measures particle distribution by laser diffraction (for instance, Malvern Mastersizer etc.).
  • Voglibose, acarbose or miglitol of the present invention having a d 50 value in the range of 10 ⁇ to 600 ⁇ can be bought and used as a product which is commercially provided in this form.
  • voglibose, acarbose or miglitol having a d 50 value in the range of 10 ⁇ to 600 ⁇ can also be obtained by pulverizing a product having a coarser particle size singly or with an excipient (for instance microcrystalline cellulose etc.).
  • pulverization can be performed by using the methods of impact mill, jet mill, blade mill etc. Pulverization can be performed before preparation of the pharmaceutical composition comprising voglibose, acarbose or miglitol as the active agent as well as during preparation of the pharmaceutical composition of the present invention or before post- production storage of the pharmaceutical composition prepared.
  • pulverization is performed by the impact of the rotating blades in the device.
  • compositions of the present invention comprising voglibose, acarbose or miglitol can be prepared in the dosage forms such as tablet, effervescent tablet, effervescent granule, effervescent dry powder, film coated tablet, enterically coated tablet, dry powder, granule, capsule, prolonged release tablet, modified release tablet, delayed release tablet.
  • the pharmaceutical compositions of the present invention comprising voglibose, acarbose or miglitol are preferably in the form of effervescent tablet, tablet, film coated tablet modified release tablet or sachet.
  • the pharmaceutical composition obtained can be formed into any abovementioned dosage form.
  • the composition is in tablet form
  • the tablets obtained can be treated with film coating agents for instance sugar based coating agents, water soluble film coating agents, enteric coating agents, delayed release coating agents or coating compositions comprising a combination thereof.
  • Saccharose can be used singly or optionally with any of the agents such as talc, calcium carbonate, calcium phosphate, calcium sulphate, gelatine, gum arabic, polyvinylpyrrolidone and pullulan or a combination thereof as the sugar based coating agent.
  • the water soluble film coating agent can be selected from cellulose derivatives such as hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methyl hydroxyethyl cellulose and sodium carboxymethyl cellulose; synthetic polymers such as polyvinyl acetal diethyl aminoacetate, aminoalkyl methacrylate copolymers and polyvinylpyrrolidone and polysaccharides such as pullulan or combinations thereof.
  • the enteric coating agents can be selected from cellulose derivatives such as hydroxypropyl methyl cellulose phthalate, hydroxypropyl methyl cellulose acetate succinate, carboxymethyl ethyl cellulose, cellulose acetate phthalate; acrylic acid derivatives such as methacrylic acid copolymer L, methacrylic acid copolymer LD and methacrylic acid copolymer S and natural substances such as shellac or combinations thereof.
  • the delayed release coating agents can be selected from cellulose derivatives such as ethyl cellulose; acrylic acid derivatives such as aminoalkyl methacrylate copolymer RS, ethyl acrylate-methyl methacrylate copolymer emulsion or combinations thereof.
  • compositions of the present invention comprising voglibose, acarbose or miglitol can comprise various excipients in addition to the active agent voglibose, acarbose or migltiol.
  • excipient selected from a group comprising disintegrant, diluent, lubricant, glidant, binder, effervescent couple comprising at least one acidic agent and at least one basic agent, colouring agent, pH regulating agent, surfactant, stabilizing agent, sweetener and/or taste regulating agent, flavouring agent in addition to the active agent voglibose, acarbose or
  • the disintegrant that can be used in the pharmaceutical compositions of the present invention comprising voglibose, acarbose or miglitol can be selected from a group comprising carboxymethyl cellulose, carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, croscarmellose sodium, crospovidone, hydroxypropyl cellulose, microcrystalline cellulose, methyl cellulose, chitosan, starch, sodium starch glycolate.
  • the diluent that can be used in the pharmaceutical compositions of the present invention comprising voglibose, acarbose or miglitol can be selected from a group comprising calcium carbonate, calcium phosphate, tribasic calcium phosphate, calcium sulphate, microcrystalline cellulose, dextrose, fructose, lactitol, lactose, magnesium carbonate, magnesium oxide, maltitol, maltodextrin, maltose, mannitol, simethicone, sorbitol, starch, sodium chloride, sucrose, talc, xylitol.
  • the lubricant that can be used in the pharmaceutical compositions of the present invention comprising voglibose, acarbose or miglitol can be selected from a group comprising calcium stearate, magnesium stearate, polyethylene glycol, sodium benzoate, potassium benzoate, sodium lauryl sulphate, talc, stearic acid, zinc stearate.
  • the glidant that can be used in the pharmaceutical compositions of the present invention comprising voglibose, acarbose or miglitol can be selected from a group comprising tribasic calcium phosphate, colloidal silicone dioxide, magnesium silicate, magnesium trisilicate, talc.
  • the binder that can be used in the pharmaceutical compositions of the present invention comprising voglibose, acarbose or miglitol can be selected from a group comprising carboxymethyl cellulose sodium, ethyl cellulose, gelatine, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hypromellose, magnesium aluminium silicate, maltodextrin, methyl cellulose, povidone, starch.
  • the acidic agent composing the effervescent couple comprising at least one acidic agent and at least one basic agent that can be used in the pharmaceutical compositions of the present invention comprising voglibose, acarbose or miglitol can be selected from a group comprising organic acids such as malic acid, citric acid, tartaric acid, fumaric acid; and the basic agent can be selected from a group comprising agents such as sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate.
  • the pH regulating agent that can be used in the pharmaceutical compositions of the present invention comprising voglibose, acarbose or miglitol can be selected from a group comprising citrate, phosphate, carbonate, tartarate, fumarate, acetate and amino acid salts.
  • the surfactant that can be used in the pharmaceutical compositions of the present invention comprising voglibose, acarbose or miglitol can be selected from sodium lauryl sulphate, polysorbate, polyoxyethylene, polyoxypropylene glycol and similar agents.
  • the stabilizing agent that can be used in the pharmaceutical compositions of the present invention comprising voglibose, acarbose or miglitol can be selected from a group comprising tocopherol, tetrasodium edetate, nicotinamide, cyclodextrin.
  • the sweetener and/or taste regulating agent that can be used in the pharmaceutical compositions of the present invention comprising voglibose, acarbose or miglitol can be selected from a group comprising acesulfame, aspartame, dextrose, fructose, maltitol, maltose, mannitol, saccharine, saccharine sodium, sodium cyclamate, sorbitol, sucralose, sucrose, xylitol, sodium chloride.
  • flavouring agent that can be used in the pharmaceutical compositions of the present invention comprising voglibose, acarbose or miglitol can be selected from menthol, lemon, orange, vanilla, strawberry, raspberry, caramel and similar flavours.
  • compositions of the present invention comprising voglibose, acarbose or miglitol can optionally comprise a second active agent in addition to voglibose, acarbose or miglitol.
  • the second active agent can be selected from antacid, anticholinergic, antispasmodic, antiemetic, antidiabetic, antipropulsive, antiallergic, antidiarrheal, antiobesity, antithrombotic, antifibrinolytic, antianemic, antihypertensive, antifungal, antipruritic, antipsoriatic, antibiotic, antiseptic, antiacneantibacterial, antimycotic, antiviral, antineoplastic, antiarrhythmic, antiadrenergic, antiepileptic, anti-parkinson, antiprotozoal, anthelmintic, anti-inflammatory, diuretic, laxative, sulphonamide, imidazole, corticosteroid
  • the second active agent that can optionally be used in the pharmaceutical compositions comprising voglibose, acarbose or miglitol can be selected from a group comprising repaglinide belonging to the groups of meglitinides; acetohexamide, glindeclamide, glibornuride, gliclazide, gliquidone, glimepiride, glipizide, chlorpropamide, tolbutamide belonging to the group of sulfonylureas; pioglitazone, rosiglitazone, rivoglitazone, rosiglitazone maleate, pioglitazone hydrochloride, troglitazone belonging to the group of thiazolidinediones; phenformin, metformin, metformin hydrochloride belonging to the group of biguanides; dipeptidyl peptidase-4 inhibitors sitagliptin, vildagliptin, saxa
  • the pharmaceutical compositions comprising voglibose, acarbose or miglitol comprise metformin hydrochloride as the second active agent.
  • the present invention relates to pharmaceutical compositions
  • dg 5 value of voglibose, acarbose or miglitol and metformin hydrochloride is in the range of 10 to 600 ⁇ .
  • the pharmaceutical composition of the present invention can be obtained by ⁇ mixing the active agent voglibose, acarbose or miglitol and the second active agent if available homogeneously and adding at least one of the abovementioned excipients if required or
  • the formulations of the present invention are preferably produced by production methods comprising granulation process.
  • the inventors have seen that the formulations comprising the granules produced by granulation process and having d 5 o value less than 800 ⁇ , preferably in the range of 10 ⁇ to 800 ⁇ , more preferably in the range of 50 ⁇ to 750 ⁇ , for instance in the range of 60, 70, 80, 90, 100, 1 10, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250 to 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 450, 500, 530, 550, 600 have free flow, dose uniformity and required dissolution properties.
  • the present invention relates to pharmaceutical compositions comprising voglibose, acarbose or miglitol and optionally a second active agent, for instance metformin hydrochloride wherein d 50 value of the granules are less than 800 ⁇ , preferably in the range of 10 ⁇ to 800 ⁇ , more preferably in the range of 50 ⁇ to 750 ⁇ .
  • Said granules comprise at least one active agent and/or at least one excipient.
  • said granules may comprise only one or more active agents or only one or more excipients or a combination of one or more active agents and one or more excipients.
  • Said active agent and excipients can be comprised in the mixture granulated as well as in the granulation solution.
  • the pharmaceutical composition of the present invention can be used in prevention and treatment of non-insulin dependent type II diabetes.
  • Example 1 Effervescent tablet formulation comprising Voglibose and Metformin HCI
  • Voglibose, effervescent acid and effervescent base are granulated.
  • the granules obtained are dried and mixed with metformin HCI and other excipients.
  • the final mixture is compressed in tablet compression machine.
  • Example 2 Effervescent tablet formulation comprising acarbose
  • Acarbose, effervescent acid and effervescent base are granulated.
  • the granules obtained are dried and mixed with other excipients.
  • the final mixture is compressed in tablet compression machine.
  • Example 3 Modified release tablet formulation comprising voglibose
  • Voglibose and other excipients are mixed.
  • the final mixture obtained is compressed in tablet compression machine.
  • the tablets obtained are coated with the coating agent and dried.
  • Example 4 Film tablet formulation comprising miglitol
  • Voglibose and other excipients are mixed.
  • the final mixture obtained is compressed in tablet compression machine.
  • the tablets obtained are coated with the coating agent and dried.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques contenant du voglibose, de l'acarbose ou du miglitol, qui sont destinées au traitement du diabète de type II (non insulinodépendant).
PCT/TR2013/000050 2012-01-31 2013-01-31 Compositions pharmaceutiques contenant un inhibiteur de l'alpha-glucosidase WO2013115741A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2012/01092 2012-01-31
TR201201092 2012-01-31

Publications (1)

Publication Number Publication Date
WO2013115741A1 true WO2013115741A1 (fr) 2013-08-08

Family

ID=48048162

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2013/000050 WO2013115741A1 (fr) 2012-01-31 2013-01-31 Compositions pharmaceutiques contenant un inhibiteur de l'alpha-glucosidase

Country Status (1)

Country Link
WO (1) WO2013115741A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015124195A (ja) * 2013-12-27 2015-07-06 株式会社三和化学研究所 ミグリトール含有コーティング製剤

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001002567A (ja) * 1999-04-20 2001-01-09 Takeda Chem Ind Ltd 水溶性薬物を含有する徐放性製剤
WO2009071219A2 (fr) * 2007-12-08 2009-06-11 Bayer Schering Pharma Aktiengesellschaft Comprimé dispersible oral
WO2009135951A2 (fr) * 2008-05-09 2009-11-12 Atacama Labs Oy Procédé pour préparer un comprimé contenant de la metformine
WO2011134962A2 (fr) * 2010-04-27 2011-11-03 Bayer Pharma Aktiengesellschaft Comprimé à désintégration orale contenant de l'acarbose
WO2012093972A1 (fr) * 2011-01-06 2012-07-12 Mahmut Bilgic Formes galéniques solubles dans l'eau

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001002567A (ja) * 1999-04-20 2001-01-09 Takeda Chem Ind Ltd 水溶性薬物を含有する徐放性製剤
WO2009071219A2 (fr) * 2007-12-08 2009-06-11 Bayer Schering Pharma Aktiengesellschaft Comprimé dispersible oral
WO2009135951A2 (fr) * 2008-05-09 2009-11-12 Atacama Labs Oy Procédé pour préparer un comprimé contenant de la metformine
WO2011134962A2 (fr) * 2010-04-27 2011-11-03 Bayer Pharma Aktiengesellschaft Comprimé à désintégration orale contenant de l'acarbose
WO2012093972A1 (fr) * 2011-01-06 2012-07-12 Mahmut Bilgic Formes galéniques solubles dans l'eau

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015124195A (ja) * 2013-12-27 2015-07-06 株式会社三和化学研究所 ミグリトール含有コーティング製剤

Similar Documents

Publication Publication Date Title
RU2481110C2 (ru) Лекарственные формы с улучшенными фармакокинетическими свойствами
ES2264967T3 (es) Composicion de gliburida.
EP3287438A1 (fr) Sel de choline d'un composé cyclobutène-dione substitué anti-inflammatoire
WO2007026864A1 (fr) Procédé de préparation de composition pharmaceutique ayant une meilleure capacite de désintégration
US20040166162A1 (en) Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
WO2013115742A1 (fr) Composition pharmaceutique contenant un inhibiteur de l'alpha-glucosidase
WO2013115744A1 (fr) Procédé de préparation de compositions pharmaceutiques (effervescentes) contenant un inhibiteur de l'apha-glucosidase (p. ex. voglibose et metformine)
TW202237145A (zh) 莫奈皮拉韋的醫藥組成物
WO2013115738A1 (fr) Acarbose micronisée
WO2013109227A1 (fr) Compositions pharmaceutiques contenant du ceftibutène
WO2013115740A1 (fr) Combinaison synergique contenant un dérivé de méglitinide et de l'acide lipoïque
WO2013095316A1 (fr) Combinaison synergique comprenant un agent anti-diabétique
WO2013077824A1 (fr) Procédé de fabrication d'une préparation comprenant de la metformine
WO2013074049A1 (fr) Metformine micronisée
WO2014104989A1 (fr) Compositions pharmaceutiques comprenant de l'aripiprazole
WO2013115741A1 (fr) Compositions pharmaceutiques contenant un inhibiteur de l'alpha-glucosidase
EP2243468A1 (fr) Compositions comprenant de la diméboline et se désintégrant oralement
WO2013077819A1 (fr) Préparations pharmaceutiques comprenant du natéglinide
WO2013077822A1 (fr) Nouvelles préparations pour le traitement du diabète
WO2013077825A1 (fr) Procédé de fabrication d'une préparation comprenant de la metformine
WO2014007775A1 (fr) Nouvelle formulation à dissolution rapide
WO2013109230A1 (fr) Compositions pharmaceutiques contenant du tadalafil
ES2435966T3 (es) Combinaciones de vildagliptina y glimepirida
ES2654331T3 (es) Comprimidos de ibuprofeno de sodio y procedimientos de fabricación de composiciones farmacéuticas que incluyen ibuprofeno de sodio
WO2013100879A1 (fr) Compositions pharmaceutiques contenant de la quétiapine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13714362

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13714362

Country of ref document: EP

Kind code of ref document: A1